Overview
Biotia is a health tech company advancing infectious disease diagnostics for challenging infections[2]. Founded as a spinout of the Jacobs Technion-Cornell Institute at Cornell Tech[2], the company is based in New York City[2] and operates a high-complexity, CLIA-certified diagnostic laboratory[2]. Biotia is recognized as part of the New York AI scene[1] within the biotech-AI category[1]. As of available records, the company has approximately 26 employees[3] and operates within the biotechnology research industry[3].
Business address: 30-02 48th Ave, New York, New York, 11101. [6]
Growth & traction
Funding & milestones
1 events found for Biotia · 2026
Venture / equity1 source$9M
Reported amount $9,000,000
Biotia Raises $9M to Close the Diagnostic Gap for Recurrent and Culture-Negative UTIs
Recorded history so far. Original currencies are preserved; amounts in different currencies are not added together. Debt, grants, acquisitions and listings are separate event types. Undated events appear last.
Leadership & org chart
In the news
- The AlleyWatch Startup Daily Funding Report: 10/2/2026The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 10/2/2026 featuring funding details for TriGemX Bio, Walapay, and much more.
- Biotia Raises $9M to Close the Diagnostic Gap for Recurrent and Culture-Negative UTIsAs many as 1 in 3 urine cultures come back negative, yet the burning and urgency keep coming. A Cornell Tech spinout says the infection is often still there: in a study of 200+ culture-negative samples, its sequencing test found a pathogen in 63% of them. Biotia just raised $9M to take that approach into places where a wrong guess costs even more, including a type of infection that surgeons dread.
- The AlleyWatch Startup Daily Funding Report: 10/1/2026The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 10/1/2026 featuring funding details for Daptic, Biotia, and much more.
Something wrong or missing? Send an update. Fixed within 24 hours.